Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
156 Results for "
B-Raf inhibitor
" in MedChemExpress (MCE) Product Catalog:
Products (156)
156 Results for "B-Raf inhibitor" in MCE Product Catalog:
Cat. No.: HY-12847
CAS No.: 1163719-91-2
CCT241161 is an orally active pan-RAF inhibitor with IC50s of 3, 6, 10, 15 and 30 nM for LCK, CRAF, SRC, V600E-BRAF and BRAF, respectively. CCT241161 shows good activity to in BRAF and NRAS mutant melanomas. CCT241161 also exhibits anticancer cell proliferative activity .
Cat. No.: HY-77113
CAS No.: 918504-27-5
B-Raf IN 11 is a B-Raf V600E mutant kinase inhibitor with an IC50 of 76 nM, and exhibits an IC50 of 238 nM against wild-type B-Raf kinase. B-Raf IN 11 inhibits the kinase activities of B-Raf V600E mutant and wild-type B-Raf kinase. B-Raf IN 11 is applicable to relevant research on colorectal cancer .
Cat. No.: HY-18227
CAS No.: 950736-05-7
B-Raf IN 1 is a potent and selective B-Raf kinase inhibitor with an IC50 of 24 nM.
Synonyms: B-Raf IN 10
Uplarafenib (B-Raf IN 10) (Compound C09) is a BRAF inhibitor with an IC50 between 50 and 100 nM. Uplarafenib shows antitumor activity .
Cat. No.: HY-P10438
Cat. No.: HY-18507
CAS No.: 1093380-42-7
Target:
Research Areas:
AD57 is an orally active multikinase inhibitor, inhibits RET, BRAF, S6K and Src, with greatly reduces mTOR activity .
Cat. No.: HY-149380
CAS No.: 3057544-65-4
Vem-L-Cy5 (compound 3)，modified with the NIR fluorophore cyanine-5 (Cy5)，is a Vemurafenib (HY-12057)-based inhibitor of BRAF. Vem-L-Cy5 targets to BRAF V600E，and also inhibits MEK phosphorylation. Vem-L-Cy5 has cell permeability，and inhibits cell growth of many types of cancer .
MAPK-IN-2 (compound 3h) is a potent MAPK inhibitor with antineoplastic activity. MAPK-IN-2 inhibits cancer cell proliferation among serval cancer cell lines, and suppresses MAPK pathway with potant efficacy (EGFR WT IC50=281 nM, c-MET IC50=205 nM, B-RAF WT IC50=112 nM, and CDK4/6 IC50=95 and 184 nM, respectively). MAPK-IN-2 even shows a remarkable potency against mutated EGFR and B-RAF (EGFR T790M IC50=69 nM and B-RAF V600E IC50=83 nM) .
Target:
Research Areas:
GSK-114 is a highly selective, orally active TNNI3K inhibitor (IC50= 25 nM). GSK-114 shows a 40-fold selectivity for TNNI3K over B-Raf kinase (IC50= 1 μM). Cardiac troponin I-interacting kinase (TNNI3K or CARK) is a member of the tyrosine-like kinase family that is selectively expressed in heart tissue .
Cat. No.: HY-P10436
CAS No.: 2411851-64-2
Cat. No.: HY-126298
CAS No.: 2340020-82-6
RAF mutant-IN-1 is a RAF kinase inhibitor, extracted from patent WO2019107987A1, with IC50 values of 21 nM, 30 nM and 392 nM for C-RAF 340D/Y341D, B-RAF V600E and B-RAF WT, respectively .
Cat. No.: HY-15199
CAS No.: 1227678-26-3
Synonyms: CEP-32496 hydrochloride; RXDX-105 hydrochloride
Agerafenib hydrochloride is a highly potent and orally efficacious inhibitor of BRAF V600E with a Kd of 14 nM.
Cat. No.: HY-144271
CAS No.: 2695505-82-7
RAF-IN-1 is a RAF inhibitor with IC50 values of 29.4 nM, 3.8 nM, and 36 nM against human recombinant bRAF V600E, cRAF, and bRAF WT enzymes, respectively. RAF-IN-1 suppresses RAF enzymatic activity and reduces cancer cell proliferation. RAF-IN-1 can be used for cancer research .
Cat. No.: HY-51424R
CAS No.: 918505-84-7
PLX-4720 (Standard) is the analytical standard of PLX-4720. This product is intended for research and analytical applications. PLX-4720 is a potent and selective inhibitor of B-RafV600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), and 10-fold selectivity for B-RafV600E than wild-type B-Raf.
Cat. No.: HY-51424S
CAS No.: 1304096-50-1
Cat. No.: HY-137488
CAS No.: 2417296-82-1
PROTAC BRAF-V600E degrader-2 is a PROTAC degrader targeting BRAF-V600E. The Kd values of PROTAC BRAF-V600E degrader-2 for BRAF and BRAF-V600E are 14.4 nM and 9 nM, respectively. PROTAC BRAF-V600E degrader-2 selectively degrades BRAF-V600E but does not degrade wild-type BRAF. PROTAC BRAF-V600E degrader-2 inhibits the MEK/ERK kinase cascade and suppresses the growth of melanoma cells. PROTAC BRAF-V600E degrader-2 can be used in studies related to melanoma and colon cancer .
Cat. No.: HY-179012
CDC20/HSP90-IN-1 (Compound 2b) is a Cdc20/Hsp90 inhibitor with a Kd of 16.2 μM for Cdc20 and a Kd of 0.241 μM for Hsp90α. CDC20/HSP90-IN-1 exerts potent antitumor activity through reducing p53-mediated Cdc20, upregulating Bim, downregulating Cyclin B1 expression, and disturbing B-Raf and AKT pathways via destroying Hsp90 chaperone function. CDC20/HSP90-IN-1 overcomes Vemurafenib (HY-12057)-induced resistant melanoma .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
